A new generation of low-molecular weight heparins with special reference to bemiparin

Bogachev V.Yu.

doi:https://doi.org/

Bogachev V.Yu.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

A new generation of low-molecular weight heparins with special reference to bemiparin

Authors:

Bogachev V.Yu.

More about the authors

Journal: Journal of Venous Disorders. 2011;5(2): 64‑69

Read: 4053 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Bogachev VYu. A new generation of low-molecular weight heparins with special reference to bemiparin. Journal of Venous Disorders. 2011;5(2):64‑69. (In Russ.)

Подписка 2026 Флебология (Journal of Venous Disorders)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Efficacy and Safety of the Oral Anticoagulant DIMOLEGIN Compared to Enoxaparin Sodium for the Prevention of Venous Thromboembolism Following Major Joint Replacement Surgery (hip or knee arthroplasty): A Randomized, Double-Blind, Multicenter Trial. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):577-585

Abstract:

A literature review of pharmacological properties and clinical applications of bemiparin, a low-molecular weight heparin of the second generation, is presented. This new agent has been developed for the prevention of venous thromboembolic complications.

Keywords:

venous thromboembolic complications

VTEC

heparin

low-molecular weight heparins

LMWH

enoxaparin

bemiparin

zibor

Authors:

Bogachev V.Yu.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Close metadata

References:

Rutherford R.B. (ed.) Vascular surgery. ELSEVIER Saunders 2005;ISBN 0-7216-0299-1.
Caprini J., Wentworth D. Venous thrombosis prophylaxis. Venous and Lymphatic Diseases. Eds. N. Labropoulos and G. Stansby. Taylor&Francis 2006;ISBN-13:978-0-8247-2923-3;173-204.
Gainor C., Vanscoy G., Niccolai C., Rihn T. Pharmacologic and liability considerations of therapeutic interchange with low-molecular-weight heparins. Hospital Pharmacy 2003;38:7:652-658.
Geerts W., Berqvist D., Pineo G. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:Suppl:381S-453S.
Kearon C., Kahn S., Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:Suppl:354S-545S.
Harrington R., Becker R., Cannon P. et al. Antithrombotic therapy for non- ST- segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:Suppl:670S-707S.
Yavelov I.S. Preparaty nizkomolekulyarnogo geparina: osnovnye svoistva i vozmozhnosti sozdaniya analogov. Klin farmakol i ter 2010;19:56-63.
Blossom D., Kallen A., Patel P. et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008;359:2674-2684.
Hughes S. Enoxaparin now affected by heparin contaminant. http://www.the-heart.org/articIe/859795.do.
Kishimoto T., Viswanathan K., Ganguly T. et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-2467.
Gray E., Mulloy B. Biosimilar low molecular heparin products. J Thromb Haemost 2009;7:1218-1221.
Planes A. Review of bemiparin sodium-a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Exp Opin Pharmacother 2003;4:9:1551-1561.
Falkon L., Saenz-Campos D., Antonijoan R. et al. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11). A three way cross-over study in healthy volunteers. Thromb Res 1995;78:77-86.
Falkon L., Bayes M., Frontera G. et al. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers- a dose-finding study within the therapeutical range. Thromb Haemost 1997;77:133-136.
Collignon F., Frydman A., Caplain et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins- dalteparin, enoxaparin, nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995;73:630-640.
Eriksson B.I., Soderberg K., Widlund L. et al. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995;73:398-401.
Breddin H.K. Reviparin sodium- a new low molecular weight heparin. Exp Opin Pharmacother 2002;3:173-182.
Santamaria A., Juarez S., Reche A. et al. Low-molecular weight heparin, Bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: THE ESFERA study. Clin Practice 2006;60:518-525.
Borrell M., Antonijoan R.M., Ortin R. et al. Pharmacokinetic profiles of two LMWH: Bemiparin 3,500 IU and Enoxaparin 4,000 IU after subcutaneous administration in healthy volunteers. Thromb Haemost 2001;86: Suppl:CD3578:Abstract.
Depasse F., Gonzalez De Suso M., Lagoutte I. et al. Comparative study of the pharmacokinetic profiles of two LMWH- Bemiparin (3,500 IU anti-Xa) and Tinzaparin (4,500 IU anti-Xa) – administered subcutaneously to healthy male volunteers. Thromb Res 2003;109:109-117.
Kakkar V.V., Howes J., Sharma V., Kadziola Z. A comparative, double-blind, randomized trial of new-second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism in patients undergoing hip arthroplasty. Thromb Haemost 2000;83:523-529.
Navarro-Quilis A., Castellet E., Rocha E. et al. Efficacy and safety of bemiparin compared with Enoxaparin in the prevention of thromboembolism after total knee arthroplasty. A randomized double-blind clinical trial. J Thromb Haemost 2003;1:425-432.
Planes A., Vochelle M., Fagola M., Bellaud M. Comparison of two low molecular weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coagul Fibrinol 1998;9:499-505.
Planes A., Vochelle N., Gonzalez De Suso M.J., Claracq J.P. Profilaxis antitrombotica poscirurgia ortopedica con bemiparina, heparina de bajo peso molecular de segunda generacion. Rev Anestesiol Reanim 2001;48:258-263.
Moreno Gonzalez E., FontcubertaJ., De La Llama F. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. Hepatogastroenterology 1996;43:744-747.